ArticleClinics in shoulder and elbow2022
Platelet-rich plasma versus corticosteroid injections for rotator cuff tendinopathy: a comparative study with up to 18-month follow-up.
Article in Clinics in shoulder and elbow, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Ultrasound-guided platelet-rich plasma versus corticosteroid injection for supraspinatus tendinopathy: a randomized comparative study.BMC musculoskeletal disorders · 2026Trial
- Adherence rates to the Minimum Information for Studies Evaluating Biologics in Orthopedics guidelines for clinical studies on platelet-rich plasma for the treatment of lateral epicondylitis: a systematic review.Clinics in shoulder and elbow · 2026Review
- The efficacy of platelet-rich plasma compared to corticosteroids for partial-thickness rotator cuff tears: a randomized controlled trial.JSES international · 2026Article
- Platelet-rich plasma in the management of musculoskeletal disorders: a narrative review of clinical evidence and practical considerations.Frontiers in medicine · 2026Review
- Review
- Epigallocatechin-3-Gallate (EGCG)-Loaded Hyaluronic Acid Hydrogel Seems to Be Effective in a Rat Model of Collagenase-Induced Achilles Tendinopathy.Journal of functional biomaterials · 2025Article
- Review
- Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears: Findings from a Retrospective Observational Study.Biomedicines · 2024Article
- Combination effect of Chinese kidney-tonifying granules and platelet-rich plasma gels on enhancing bone healing in rat models with femur defects.Journal of orthopaedic surgery and research · 2023Article
- Postoperative Rehabilitation of Elbow Pain.Ewha medical journal · 2023Review
- Recent Nonoperative Treatment of Elbow Pain.Ewha medical journal · 2023Review
- Differential Diagnosis of Elbow Pain.Ewha medical journal · 2023Review
- Role of platelet-rich plasma in the treatment of rotator cuff tendinopathy.World journal of orthopedics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the complications involved in corticosteroid (CS) injections, subacromial platelet-rich plasma (PRP) injections may provide a valid alternative to CS in the treatment of rotator cuff (RC) tendinopathy.
methodsWe retrospectively reviewed a total of 98 patients affected by RC tendinopathy who were treated with either subacromial injection of PRP or CS. The PRP group received three injections of autologous PRP at 2 weeks interval, and the CS group received one injection of CS. The Western Ontario Rotator Cuff Index (WORC) was the primary outcome measure, while the secondary outcome measures were the visual analog scale (VAS), range of motion (ROM), and need for cuff repair surgery, which were analyzed at intervals of 6, 12, and 18 months.
resultsA total of 75 patients were included in the analysis (PRP, n=35; CS, n=40). The mean follow-up for PRP was 21.1±8.7 months and for CS was 33.6±16.3 months (p<0.001). Both groups showed improvement in WORC, VAS, and ROM. No significant differences were detected between the two groups in any of the primary (WORC) or secondary outcomes over 6, 12, and 18 months (all p>0.05). No adverse events were detected.
conclusionsBoth treatments improved patient symptoms, but neither resulted in a significantly better outcome in this series of patients. PRP can be a safe and feasible alternative to CS, even at long-term follow-up, to reduce local and systemic effects involved with CS injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.